ArticlePediatric radiology2026
Fat-containing liver lesions expanding the magnetic resonance imaging signature of hepatoblastoma.
Article in Pediatric radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFat-containing liver lesions have been widely discussed in the radiology literature and include various benign and malignant lesions. However, data on the presence and imaging characteristics of intralesional fat in hepatoblastoma remain limited.
objectiveTo investigate the presence of intralesional fat in hepatoblastoma using dual-echo magnetic resonance imaging (MRI) and to correlate imaging findings with histopathology. MATERIALS AND
methodsThis retrospective study included 22 pediatric patients with hepatoblastoma who underwent pretreatment MRI with a dual-echo gradient-recalled echo sequence. Qualitative visual assessment and semiquantitative analysis using region-of-interest (ROI) measurement were performed to evaluate intralesional fat. Histopathology was accepted as the reference standard for fat detection.
resultsTwenty-two patients (8 girls, 14 boys; median age, 11.5 months; range, 3-192 months) with pretreatment dual-echo MRI were included. Histopathologic evaluation demonstrated intratumoral fat in 10 of 22 tumors (45%). On MRI, intralesional fat was detected in eight lesions. Six lesions showed both histopathologic fat and signal loss on dual-echo MRI, whereas four lesions had histopathologic fat without detectable signal loss (< 1%). Two lesions demonstrated signal loss on MRI despite the absence of histopathologic fat. Using histopathology as the reference standard, MRI demonstrated a sensitivity of 60% and a specificity of 83.3% with an overall accuracy of 72.7% for detecting intratumoral fat in hepatoblastoma. Interobserver agreement for the four-level visual fat score was substantial (weighted Cohen's κ=0.789).
conclusionIntralesional fat can be present in hepatoblastoma and may be detected on MRI, expanding the recognized imaging features of this tumor.
Indexed as
Identifiers
42340424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.